Recent efforts have focused on defining the pre-clinical stages of psoriatic arthritis (PsA), with the European Alliance of Associations for Rheumatology (EULAR) proposing a three-phase progression: individuals at risk for PsA, those with subclinical PsA, and those with early clinically evident PsA. New evidence from retrospective observational studies supports the practicality of disease interception: preventing PsA in individuals with psoriasis through early treatment, especially with biologic disease-modifying anti-rheumatic medications.

Some biologics used for psoriasis like IL-17 and IL-23 inhibitors can reduce PsA incidence; findings have not been uniformly positive, though. Tumour necrosis factor inhibitors, despite their efficacy in skin disease, have not consistently reduced PsA risk. Such  inconsistencies reinforce the need for prospective studies to validate interception strategies and refine risk stratification tools. This review addresses current challenges in early PsA research, including finding risk factors, language comparisons, and preventing psoriasis.

Reference: López-Medina C, McGonagle D, Gossec L. Subclinical psoriatic arthritis and disease interception-where are we in 2024? Rheumatology (Oxford). 2025 Jan 1;64(1):56-64. doi: 10.1093/rheumatology/keae399. PMID: 39150442; PMCID: PMC11701312.